INTRODUCTION
To investigate to what extent coronavirus vectors can induce antitumoral and antiviral humoral and cellular immune responses in vivo, we generated vectors based on mouse hepatitis virus to be used for studies of the immunological response to antigens expressed on murine dendritic cells. In these vectors, the structural genes encoding the viral envelope (E) and membrane (M) proteins have been deleted and replaced by sequences encoding a reporter protein (green fluorescent protein [GFP]) fused to an * Kantonal Hospital St.Gallen, 9007 St.Gallen, Switzerland.
Coronavirus-based vectors are currently considered a promising means to deliver multiple heterologous genes to specific target cells. During replication of the coronavirus RNA genome in the host cell cytoplasm, 6-8 subgenomic mRNAs encoding for structural and accessory proteins are produced. Most of these genes can be replaced by heterologous genes without affecting RNA replication. 1, 2 This allows the insertion of more than 6 kb into coronavirus-based vectors. [1] [2] [3] [4] Replication without a DNA intermediate in the host cell cytoplasm makes insertion of vector-derived sequences into the host cell genome unlikely. This, together with replacement of structural viral genes in the vector by heterologous sequences, makes these noninfectious vectors safe. An important consideration for viral vaccine vectors is the potential to efficiently deliver genetic material to specific target cells. Targeting of viral vaccine vectors to professional antigen-presenting cells, such as dendritic cells (DCs), is highly desirable in order to optimize vaccine efficacy. 5, 6 The receptors of human coronavirus 229E and mouse hepatitis virus (MHV) are expressed on DCs, [7] [8] [9] indicating that vectors based on these viruses can be used to deliver genetic cargo efficiently to DCs via receptor-mediated transduction. 1 Therefore, recombinant MHV vectors in the context of a murine model can serve as a paradigm for the development and evaluation of coronavirus vaccine vectors suitable for in vitro and in vivo transduction of human DCs. immunogenic epitope (e.g., LCMV gp33). We generated packaging cells stably expressing MHV E and M proteins and transfected MHV vector RNA into these by electroporation. Vector RNA-transfected packaging cells replicated and transcribed recombinant vector RNA as shown by reporter gene expression and syncytia formation in cell cultures. Vector RNA was packaged into viral-like particles as shown by transduction of dendritic cells after transfer of cell culture supernatants from vector transfected packaging cells. Further studies will address activation and antigen presentation of vector-transduced dendritic cells in a mouse model. Stable integration in packaging cells of the sequence encoding either MHV S, or of a chimeric S protein that will give vector particles the ability to transduce human dendritic cells, will further improve the applicability of these packaging cell lines for production of vectors for immunotherapeutical studies.
RESULTS

MHV Vector RNA Structure
We have previously established a reverse genetic system based on full-length cDNA copies of coronavirus genomes cloned and propagated in vaccinia virus. [10] [11] [12] Based on this system we have constructed a cDNA encoding a MHV prototype vector RNA using vaccinia virus-mediated homologous recombination. As illustrated in Figure 1 , the vector RNA encodes the MHV 5'-and 3'-non-translated regions, the MHV replicase, spike and nucleocapsid genes. Furthermore, we inserted a reporter gene encoding a fusion protein comprised of GFP fused to an immunogenic epitope (e.g., LCMV gp33). The MHV vector RNA can be produced by in vitro transcription from genomic DNA of the recombinant vaccinia virus.
Generation of Packaging Cell Lines
expressing MHV structural proteins E and M. These cells are based on 17 clone-1 cells that are susceptible to MHV infection. 13, 14 Genes encoding MHV E and M proteins were cloned downstream of a SV40 and CMV promoter, respectively, in a plasmid DNA conferring neomycin resistance. Using G418 selection we could obtain several stable cell clones that were analyzed for E and M protein expression. First, genomic DNA was isolated, and PCR was performed to verify integration of the E and M-encoding genes ( Fig. 2a ). Then, poly-A containing RNA was isolated as described 17 and oligo-dT-primed reverse transcription (RT) reactions followed by PCR were performed to verify expression of the E and M transcripts (Fig. 2b) . Finally, E and M protein expression was confirmed by immunofluorescence analysis using E-and M-specific antisera (data not shown).
Generation of Vector RNA-Containing VLPs and Transduction of Murine DCs
cells, the cells were monitored by fluorescence microscopy. After 24 h green fluorescent 
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transfected packaging cells to murine DCs. After 12 h green fluorescent DCs were syncytia and plaques became apparent (Fig. 3b, left panel) . To test whether VLPs dendritic cells (DCs), we transferred tissue culture supernatant of MHV vector RNA-have been formed and whether these particles are capable of transducing murine After transfection of the MHV vector RNA into E and M protein-expressing packaging detectable (Fig. 3b, right panel) . Therefore, we conclude that VLPs containing MHV vector RNAs have been formed in packaging cells and that these VLPs can be used to transduce murine DCs.
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